File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Inoperable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation (TACE): an analysis of prognostic factors in five years survivors (Abstract)

TitleInoperable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation (TACE): an analysis of prognostic factors in five years survivors (Abstract)
Authors
Issue Date2002
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uk
Citation
Joint Annual Scientific Meeting of the Association of Surgeons of Great Britain and Ireland and Society of Academic and Research Surgery (ASGBI), Dublin, Ireland, 22-24 May 2002. In British Journal of Surgery, 2002, v. 89 n. Suppl 1, p. 62, abstract no. Upper GI 21 How to Cite?
AbstractAim: To evaluate the long-term survival benefit of TACE in patients with inoperable hepatocellular carcinoma and determine prognostic factors by analysis of actual 5-year survivors. Methods: Pretreatment variables were analysed from a prospective database of 335 consecutive patients from January 1989 to December 1996. Univariate and multivariate analyses were performed to identify factors predictive of 5-year survival. Results: Complete 5-year follow-up (median 91 months) was obtained on 320 patients (275 males) who underwent a mean of 3 TACEs (range 1–41) for inoperable HCC. Median age was 59 years (range 19–83). The majority were Child-Pugh grade A (81 per cent). Median tumour size was 9 cm (1–28 cm). There were 98 (30.6 per cent) 1-year and 36 (11.3 per cent) 3-year survivors. Among the 25 (7.8 per cent) 5-year survivors, survival ranged from 60.7 to 138.8 months (median 72.3 months) and tumour size from 1 to 21 cm (median 5.3 cm), with eight tumours greater than 10 cm. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count <150 × 109 L−1 (P = 0.011), albumin >35 g L−1 (P = 0.04), α-fetoprotein <1000 ng mL−1 (P = 0.007), absence of venous invasion (P = 0.011), unilobar distribution (P = 0.027), less than three tumours (P = 0.015), and tumour size <8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin >35 g L−1 (P = 0.014), unilobar distribution (P = 0.011) and α-fetoprotein <1000 ng mL−1 (0.014) were independent predictors of 5-year survival on multivariate regressional analysis. Conclusion: Five-year survival is possible in patients with inoperable hepatocellular carcinoma. Poor prognosis is associated with a bilobar distribution, an α-fetoprotein level of >1000 ng L−1 on presentation and poor underlying liver function.
Persistent Identifierhttp://hdl.handle.net/10722/83113
ISSN
2015 Impact Factor: 5.596
2015 SCImago Journal Rankings: 2.966

 

DC FieldValueLanguage
dc.contributor.authorSuilleabhain, CBOen_HK
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorTso, WKen_HK
dc.contributor.authorYong, JLen_HK
dc.contributor.authorFan, ST-
dc.date.accessioned2010-09-06T08:37:09Z-
dc.date.available2010-09-06T08:37:09Z-
dc.date.issued2002en_HK
dc.identifier.citationJoint Annual Scientific Meeting of the Association of Surgeons of Great Britain and Ireland and Society of Academic and Research Surgery (ASGBI), Dublin, Ireland, 22-24 May 2002. In British Journal of Surgery, 2002, v. 89 n. Suppl 1, p. 62, abstract no. Upper GI 21en_HK
dc.identifier.issn0007-1323en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83113-
dc.description.abstractAim: To evaluate the long-term survival benefit of TACE in patients with inoperable hepatocellular carcinoma and determine prognostic factors by analysis of actual 5-year survivors. Methods: Pretreatment variables were analysed from a prospective database of 335 consecutive patients from January 1989 to December 1996. Univariate and multivariate analyses were performed to identify factors predictive of 5-year survival. Results: Complete 5-year follow-up (median 91 months) was obtained on 320 patients (275 males) who underwent a mean of 3 TACEs (range 1–41) for inoperable HCC. Median age was 59 years (range 19–83). The majority were Child-Pugh grade A (81 per cent). Median tumour size was 9 cm (1–28 cm). There were 98 (30.6 per cent) 1-year and 36 (11.3 per cent) 3-year survivors. Among the 25 (7.8 per cent) 5-year survivors, survival ranged from 60.7 to 138.8 months (median 72.3 months) and tumour size from 1 to 21 cm (median 5.3 cm), with eight tumours greater than 10 cm. On univariate analysis, female gender (P = 0.037), absence of ascites (P = 0.028), platelet count <150 × 109 L−1 (P = 0.011), albumin >35 g L−1 (P = 0.04), α-fetoprotein <1000 ng mL−1 (P = 0.007), absence of venous invasion (P = 0.011), unilobar distribution (P = 0.027), less than three tumours (P = 0.015), and tumour size <8 cm (P = 0.021) were significant predictors of 5-year survival. Albumin >35 g L−1 (P = 0.014), unilobar distribution (P = 0.011) and α-fetoprotein <1000 ng mL−1 (0.014) were independent predictors of 5-year survival on multivariate regressional analysis. Conclusion: Five-year survival is possible in patients with inoperable hepatocellular carcinoma. Poor prognosis is associated with a bilobar distribution, an α-fetoprotein level of >1000 ng L−1 on presentation and poor underlying liver function.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www.bjs.co.uken_HK
dc.relation.ispartofBritish Journal of Surgeryen_HK
dc.rightsBritish Journal of Surgery. Copyright © John Wiley & Sons Ltd.en_HK
dc.titleInoperable hepatocellular carcinoma treated with transcatheter arterial chemoembolisation (TACE): an analysis of prognostic factors in five years survivors (Abstract)en_HK
dc.typeConference_Paperen_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.identifier.doi10.1046/j.1365-2168.89.s.1.18_3.x-
dc.identifier.hkuros83276en_HK
dc.identifier.hkuros77845-
dc.identifier.hkuros68748-
dc.identifier.volume89-
dc.identifier.issueSuppl 1-
dc.identifier.spage62-
dc.identifier.epage62-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats